Press Releases

Date Title
Nov 10, 2022 Chimerix Responds to Rubric Capital Management
Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans DURHAM, N.C. , Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
Nov 03, 2022 Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
– ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November – – Meeting with U.S. Food and Drug Administration (FDA) Set for Fourth Quarter – – Strong Financial Position with ~$285 Million in Cash at September 30 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , Nov.
Oct 27, 2022 Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
DURHAM, N.C. , Oct. 27, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on
Sep 26, 2022 Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions
- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties - DURHAM, N.C. , Sept. 26, 2022 (GLOBE NEWSWIRE) -- Chimerix , Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully
Sep 06, 2022 Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference
DURHAM, N.C. , Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present
Aug 29, 2022 Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox
- Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA’s Discretion Over 10 Years – - Emergent BioSolutions, Inc. Payment Increases to $238M Upfront and $136.5M in Potential Milestones - DURHAM, N.C. , Aug. 29, 2022 (GLOBE NEWSWIRE) --
Aug 08, 2022 Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update
– ONC201 Phase 3 ACTION Study Planned to Initiate This Year – –~$32M in Revenue from International TEMBEXA Agreements Recently Recognized– – U.S. Anti-Trust Clearance Obtained for Sale of TEMBEXA to Emergent BioSolutions – – Conference Call at 4:30 p.m. ET Today – DURHAM, N.C. , Aug.
Aug 08, 2022 Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs
Brings 30 Years of Experience as a Former Endocyte and Novartis Regulatory Executive DURHAM, N.C. , Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
Aug 02, 2022 Chimerix to Present at Wedbush PacGrow Healthcare Conference
DURHAM, N.C. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that Chimerix management will participate in the Targeted
Aug 01, 2022 Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022
DURHAM, N.C. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on
Displaying 1 - 10 of 25
  • Print
  • Email Alerts
  • RSS Feeds
  • Search
  • Share